Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance

Stock Track11-05

Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported mixed earnings that fell short of investor expectations, particularly on the revenue front.

Corcept's Q3 revenue came in at $207.638 million, missing analyst estimates of $218.526 million by 4.98%. Despite representing a 13.75% increase from the same period last year, the revenue shortfall raised concerns among investors. The company's earnings per share (EPS) of $0.16 beat the consensus estimate of $0.14, but still marked a significant 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.

Adding to investor worries, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million. This adjustment, coupled with the Q3 revenue miss, likely contributed to the sharp sell-off. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156587177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156587177","market":"nz","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance","media":"Stock Track","content":"<p>Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported mixed earnings that fell short of investor expectations, particularly on the revenue front.</p>\n\n<p>Corcept's Q3 revenue came in at $207.638 million, missing analyst estimates of $218.526 million by 4.98%. Despite representing a 13.75% increase from the same period last year, the revenue shortfall raised concerns among investors. The company's earnings per share (EPS) of $0.16 beat the consensus estimate of $0.14, but still marked a significant 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.</p>\n\n<p>Adding to investor worries, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million. This adjustment, coupled with the Q3 revenue miss, likely contributed to the sharp sell-off. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported mixed earnings that fell short of investor expectations, particularly on the revenue front.</p>\n\n<p>Corcept's Q3 revenue came in at $207.638 million, missing analyst estimates of $218.526 million by 4.98%. Despite representing a 13.75% increase from the same period last year, the revenue shortfall raised concerns among investors. The company's earnings per share (EPS) of $0.16 beat the consensus estimate of $0.14, but still marked a significant 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.</p>\n\n<p>Adding to investor worries, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million. This adjustment, coupled with the Q3 revenue miss, likely contributed to the sharp sell-off. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1156587177","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156587177","pubTimestamp":1762305405,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"个股追踪|Corcept Therapeutics第三季度营收未达预期并下调指引后暴跌7.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its cortisol-modulating therapeutics, reported mixed earnings that fell short of investor expectations, particularly on the revenue front.\nCorcept's Q3 revenue came in at $207.638 million, missing analyst estimates of $218.526 million by 4.98%. Despite representing a 13.75% increase from the same period last year, the revenue shortfall raised concerns among investors. The company's earnings per share (EPS) of $0.16 beat the consensus estimate of $0.14, but still marked a significant 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.\nAdding to investor worries, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million. This adjustment, coupled with the Q3 revenue miss, likely contributed to the sharp sell-off. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156587177","isCrawlerRequest":true}